Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells

Cancer Research

Volumn 59, Issue 20, 1999, Pages 5102-5105

  Kawano, Tetsu ^a   Nakayama, Toshinori ^a   Kamada, Noriaki ^a   Kaneko, Yoshikatsu ^a   Harada, Michishige ^a   Ogura, Nobutaka ^a   Akutsu, Yasunori ^a   Motohashi, Shinichiro ^a   Iizasa, Toshihiko ^a   Endo, Hideharu ^a   Fujisawa, Takehiko ^a   Shinkai, Hiroshi ^a   Taniguchi, Masaru ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA INTERFERON; DACARBAZINE; GALACTOSYLCERAMIDE; LIGAND; LYMPHOCYTE ANTIGEN RECEPTOR; NIMUSTINE; VINCRISTINE;

ADULT; AGED; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; MALE; MELANOMA; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION; TUMOR CELL LINE;

ADULT; AGED; ANIMALS; ANTIGEN PRESENTATION; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; GLYCOLIPIDS; HUMANS; KILLER CELLS, NATURAL; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MELANOMA; MICE; MICE, INBRED BALB C;

EID: 0032698211     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H., Nakagawa, R., Sato, H., Kondo, E., Koseki, H., and Taniguchi, M. CD1d-restricted and TCR-medialed activation of Vα14 NKT cells by glycosylceramides. Science (Washington DC), 278: 1626-1629, 1997.
2. + NK T lymphocytes. J. Immunol., 161: 3271-3281, 1998.
3. Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Sato, H., Kondo, E., Harada, M., Koseki, H., Nakayama, T., Tanaka, Y., and Taniguchi, M. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc. Natl. Acad. Sci. USA, 95: 5690-5693, 1998.
4. - T cells in mice and humans. J. Exp. Med., 180: 1097-1106, 1994.
5. Brossay, L., Chioda, M., Burdin, N., Koezuka, Y., Casorati, G., Dellabona, P., and Kronenberg, M. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J. Exp. Med., 188: 1521-1528, 1998.
6. Spada, F. M., Koezuka, Y., and Porcelli, S. A. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J. Exp. Med., 188: 1529-1534, 1998.
7. Kawano, T., Tanaka, Y., Shimizu, E., Kaneko, Y., Kamata, N., Sato, H., Osada, H., Sekiya, S., Nakayama, T., and Taniguchi, M. A novel recognition motif of human NKT antigen receptor for a glycolipid ligand. Int. Immunol., 11: 881-887, 1999.
8. Winn, H. J. Immune mechanisms in homotransplantation. II. Quantitative assay of immunologic activity of lymphoid cells stimulated by tumor homografts. J. Immunol., 86: 228-239, 1961.
9. Mule, J. J., Shu, S., Schwarz, S. L., and Rosenberg, S. A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (Washington DC), 225: 1487-1489, 1984.
10. Mule, J. J., Shu, S., and Rosenberg, S. A. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J. Immunol., 135: 646-652, 1985.
11. Lafreniere, R., and Rosenberg, S. A. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res., 45: 3735-3741, 1985.
12. North, R. J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med., 155: 1063-1074, 1982.
13. Mizoguchi, H., O'Shea, J. J., Longo, D. L., Loeffler, C. M., McVicar, D. W., and Ochoa, A. C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (Washington DC), 258: 1795-1798, 1992.
14. Arteaga, C. L., Hurd, S. D., Winnier, A. R., Johnson, M. D., Fendly, B. M., and Forbes, J. T. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression. J. Clin. Investig., 92: 2569-2576, 1993.
15. Porcelli, S. A. The CDI family: a third lineage of antigen-presenting molecules. Adv. Immunol., 59: 1-98, 1995.
16. Timmerman, J. M., and Levy, R. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med., 50: 507-529, 1999.
17. Rosenberg, S. A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 10: 281-287, 1999.
18. Bodmer, W. F., Browning, M. J., Krausa, P., Rowan, A., Bicknell, D. C., and Bodmer, J. G. Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann. NY Acad. Sci., 690: 42-49, 1993.
19. Maeurer, M. J., Gollin, S. M., Martin, D., Swaney, W., Bryant, J., Castelli, C., Robbins, P., Parmiani, G., Storkus, W. J., and Lotze, M. T. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with down-regulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. Clin. Investig., 98: 1633-1641, 1996.
20. Pawelec, G., Zeuthen, J., and Kiessling, R. Escape from host-antitumor immunity. Crit. Rev. Oncog., 8: 111-141, 1997.